Saturday, July 13, 2013

Could Bevacizumab Help In Terms Of Glioblastoma Research?

By Rob Sutter

When it comes to the field of medical research, any kind of information is going to have my attention. However, how much attention is given to the actions being done outside of the United States? I think that great work is being done in this regard, though I'd like to place my focus on glioblastoma research for the time being. Bevacizumab is definitely on the mind and, whether you realize it or not, this potentially unfamiliar term may just make strides in the way of therapy soon enough.

I don't think that there should be any wonder why this particular tumor is focused on more than others. After all, glioma is one of the most common types, accounting for 80% of all malignant growths known. When they are found in not only the brain but even the spinal cord, surgery has proven to be difficult. Treatments have been conducted and tested in order to help them and I am sure that this will not be much of a wonder to anyone intrigued by this.

According to Medscape, the Japanese Military of Health, Labor, and Welfare have approved bevacizumab for the sake of glioblastoma research. This would be used to help malignant cases with the usage of radiation and chemo coming into play as well. The news in question is especially interesting because this was not the first time such matters were conducted. In fact, I'm sure that authorities like V.A.B.C. will tell you all about the occurrences in the past and, these as well, are worthy of a learning experience.

With bevacizumab being approved for usage in the United States beforehand, keep in mind that restrictions were put in place. The article said that it was only implemented to help recurrent cases, not those which have been newly diagnosed. Of course, there were concerns with this method. The American Society of Clinical Oncology said that this particular drug didn't exactly show a great benefit but I think that there is still potential, if it is being utilized in Japan for the sake of enhancing studies.

Is it possible that more solid results will come to the surface because of these findings? I can only hope that this is the case because glioblastoma research deserves a lot of credit. The work done is stellar, to say the least, and I would like to think that others who have paid attention to this would agree with such a sentiment. I suppose time will only tell if therapies are going to be modified and, more importantly, become more effective in the long run.

About the Author:

No comments:

Post a Comment